Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

1. FDA accepts Sarepta’s NDA for precision medicine Golodirsen

   US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug…
   Read More…

   15 Feb
2. Merck initiates three Phase III trials into Keytruda for prostate cancer

   As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials…
   Read More…

   15 Feb
3. SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe

   South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’…
   Read More…

   14 Feb
4. Erectile dysfunction: giving patients more choice and better treatments

   Many studies have found that sales of Viagra (sildenafil), a tablet used to treat erectile dysfunction in men, surge around…
   Read More…

   14 Feb
5. AbCellera and Novartis enter into multi-target partnership

   Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will…
   Read More…

   14 Feb
6. National Heart Month: how can you heal a broken heart?

   February has been designated as National Heart Month in both the UK and the US. National Heart Month aims to…
   Read More…

   13 Feb
7. MHRA recalls a further three batches of sartan-based products

   The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has announced it has recalled three more batches of irbesartan as…
   Read More…

   13 Feb
8. Dementia Consortium welcomes new partners to drug discovery collaboration

   Charity industry partnership Dementia Consortium has announced that pharmaceutical companies, Johnson & Johnson Innovation, Takeda and research organisation Evotec have…
   Read More…

   13 Feb
9. FDA grants Merck’s Keytruda priority review as first line therapy for HNSCC

   Merck has announced the US Food and Drug Administration (FDA) has granted priority review for its supplementary biologics license application…
   Read More…

   12 Feb
10. FDA clamps down on illegal dietary supplements

    The US Food and Drug Administration (FDA) has announced new measures to strengthen its regulation and oversight of dietary supplements,…
    Read More…

    12 Feb